Physician profile
Martin Ebenger
NPI 1912994609
$607.16
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256 · 2020: $30.30 · 2021: $87.05 · 2022: $233.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $175.30 | 2019-2022 | |
| Abbvie INC. | $103.70 | 2022 | |
| Mayne Pharma Commercial LLC | $94.82 | 2022 | |
| Lupin INC. | $71.67 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $40.71 | 2019-2020 | |
| Therapeuticsmd, INC. | $39.02 | 2019 | |
| Amag Pharmaceuticals, INC. | $34.95 | 2019 | |
| Allergan, INC. | $18.05 | 2019 | |
| Hologic Sales and Service, LLC | $17.02 | 2019 | |
| Amgen INC. | $11.92 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Ebenger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.